Gilead Sciences, Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: GILD · Form: DEF 14A · Filed: Mar 28, 2024 · CIK: 882095

Gilead Sciences, INC. DEF 14A Filing Summary
FieldDetail
CompanyGilead Sciences, INC. (GILD)
Form TypeDEF 14A
Filed DateMar 28, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$1 billion, $18.2 billion, $12 billion, $18.2 BILLION, $1 BILLION
Sentimentneutral

Sentiment: neutral

Topics: Gilead Sciences, GILD, DEF 14A, Proxy Statement, Executive Compensation

TL;DR

<b>Gilead Sciences, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance matters.</b>

AI Summary

GILEAD SCIENCES, INC. (GILD) filed a Proxy Statement (DEF 14A) with the SEC on March 28, 2024. Gilead Sciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 28, 2024. The filing covers the period ending May 8, 2024. The company's principal executive offices are located at 333 Lakeside Dr, Foster City, CA 94404. Gilead Sciences, Inc. is classified under SIC code 2836 for Biological Products (No Diagnostic Substances). The filing includes detailed information regarding executive compensation and equity awards for the fiscal years 2020-2023.

Why It Matters

For investors and stakeholders tracking GILEAD SCIENCES, INC., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions at the upcoming annual meeting. The detailed breakdown of equity awards and their valuations provides insight into the company's long-term incentive strategies for its key personnel.

Risk Assessment

Risk Level: low — GILEAD SCIENCES, INC. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for publicly traded companies and does not contain new material events or significant financial disclosures beyond executive compensation details.

Analyst Insight

Shareholders should review the executive compensation tables and proposals to understand how their votes will impact corporate governance and executive incentives.

Key Numbers

Key Players & Entities

FAQ

When did GILEAD SCIENCES, INC. file this DEF 14A?

GILEAD SCIENCES, INC. filed this Proxy Statement (DEF 14A) with the SEC on March 28, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by GILEAD SCIENCES, INC. (GILD).

Where can I read the original DEF 14A filing from GILEAD SCIENCES, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by GILEAD SCIENCES, INC..

What are the key takeaways from GILEAD SCIENCES, INC.'s DEF 14A?

GILEAD SCIENCES, INC. filed this DEF 14A on March 28, 2024. Key takeaways: Gilead Sciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 28, 2024.. The filing covers the period ending May 8, 2024.. The company's principal executive offices are located at 333 Lakeside Dr, Foster City, CA 94404..

Is GILEAD SCIENCES, INC. a risky investment based on this filing?

Based on this DEF 14A, GILEAD SCIENCES, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, which is standard for publicly traded companies and does not contain new material events or significant financial disclosures beyond executive compensation details.

What should investors do after reading GILEAD SCIENCES, INC.'s DEF 14A?

Shareholders should review the executive compensation tables and proposals to understand how their votes will impact corporate governance and executive incentives. The overall sentiment from this filing is neutral.

How does GILEAD SCIENCES, INC. compare to its industry peers?

Gilead Sciences operates in the biotechnology and pharmaceutical industry, focusing on the development of innovative medicines.

Are there regulatory concerns for GILEAD SCIENCES, INC.?

As a publicly traded company, Gilead Sciences is subject to SEC regulations and disclosure requirements, including the filing of proxy statements.

Industry Context

Gilead Sciences operates in the biotechnology and pharmaceutical industry, focusing on the development of innovative medicines.

Regulatory Implications

As a publicly traded company, Gilead Sciences is subject to SEC regulations and disclosure requirements, including the filing of proxy statements.

What Investors Should Do

  1. Review the detailed executive compensation breakdown for key executives.
  2. Analyze the proposals presented to shareholders for voting at the annual meeting.
  3. Assess the company's corporate governance practices as outlined in the filing.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure for public companies regarding shareholder meetings and executive compensation, and does not represent a change from previous filings of the same type.

Filing Stats: 4,457 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2024-03-28 16:07:24

Key Financial Figures

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Gilead Sciences, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. OUR VISION To create a healthier world for all people OUR MISSION To discover, develop and deliver innovative therapeutics for people with life-threatening diseases OUR CORE VALUES Integrity Doing What's Right Inclusion Encouraging Diversity Excellence Being Your Best Teamwork Working Together Accountability Taking Personal Responsibility OUR CORPORATE STRATEGY LONG-TERM AMBITIONS STRATEGIC PRIORITIES (Refreshed in 2023) Bring 10+ Transformative Therapies to Patients by 2030 Maximize Near-Term Revenue Growth Maximize Impact of Long-acting HIV Therapies Expand and Deliver on Oncology Programs Be a Biotech Employer and Partner of Choice Champion an Environment of Inclusion and Employee Growth Remove Barriers to Speed in Execution Deliver Shareholder Value in a Sustainable, Responsible Manner Letter from Our Chairman and Chief Executive Officer Dear Stockholders, Thank you for another year of support as Gilead pursues its vision of creating a healthier world for all people. Looking back on 2023, we took another big step toward making that vision a reality as we continued to deliver life-changing therapies for people around the world. Guided by the priorities we established under our corporate strategy, 2023 saw us increase the value we provide to patients, society, and our stakeholders. We delivered consistent financial results while growing our clinical pipeline and diversifying our portfolio. Thanks to the hard work and dedication of our talented employees, we are entering a new phase of promise and impact with a strong financial foundation and multiple clinical updates ahead that should enable sustainable growth. The transformation that we began at the end of 2019 is building on our legacy and allowing us to reach further than ever before. Gilead's HIV portfolio remains unmatched. Biktarvy , our once-daily oral, is the global leader in HIV treatment today. We are not stopping there, of course, and the latest innovation is giving us new long-acting treatment and prevention options to increase our impact even further. Lenacapavir is the cornerstone of these efforts, and we are preparing five additional new launches by the end of 2030 through our HIV clinical development program. Between existing therapies and new launches, we believe our antiviral portfolio is well-positioned to drive continued growth in 2024 and beyond as we work toward ending the HIV epidemic for everyone, everywhere. Our successful and fast-growing oncology business is driving strong growth for Gilead. Our transformative cancer therapy, Trodelvy , and our cell therapies, Yescarta and Tecartus , continued to reach more patients and save more lives last year. Trodelvy is now approved for three types of cancer, with multiple studies underway to explore additional opportunities, and we are proud to remain the global leader in cell therapy. In 2023, we also made progress on building out our early pipeline and capabilities for treating inflammatory diseases through both internal innovation programs and collaborations with external partners. We began 2024 by announcing our acquisition of CymaBay to complement and bolster our existing treatments for liver disease. By investing in strategic opportunities that expand our rich internal portfolio, we will advance our long-standing commitment to bringing transformational medicines to patients. Underpinning all our efforts is our commitment to health equity. In 2023, we increased our support for organizations around the world that are removing societal barriers to care and partnered with multiple organizations to help improve access and equity. We look forward to building on these efforts in 2024 and beyond. It is clear that we have tremendous opportunities ahead. We have the most talented and committed team in the industry. We have the strongest and most diverse clinical pipeline in Gilead's history, and we are well on our way to our goal of developing 10 or more transformative therapies by 2030. Finally, I would like to close by expressing my gratitude to Kevin Lofton who

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing